SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dave Gore who wrote (17383)5/13/1998 1:56:00 PM
From: Leman  Read Replies (1) of 34592
 
HYALF info Actinic Keratosis, caused by sun damage to the skin, can be the first warning of
the potential to develop skin cancer. With approximately 4 million treatments
annually, actinic keratosis represents a $240 million market in the U.S. alone. Hyal
has completed its clinical development of Solarase and is in the process of filing
for regulatory approval in a number of major jurisdictions. Solarase is licensed to
F.H. Faulding for the territories of Australia, New Zealand, Singapore and
Malaysia and to Adcock Ingram for southern Africa. Hyal is in discussions with a
number of multi-national pharmaceutical companies who are interested in licensing
Solarase elsewhere in the world.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News